InvestorsHub Logo
Followers 4
Posts 179
Boards Moderated 0
Alias Born 02/25/2012

Re: None

Monday, 10/26/2015 10:56:06 AM

Monday, October 26, 2015 10:56:06 AM

Post# of 401345
Near term Goals
ELI 200 submission in 2015 & approval in 2016
Continuing manufacturing facility´s expansion, equipment upgrade and staffing

- Loxapine & Dantrolene launch
- Filling two more opioid products in 2016
- ELI 200 product launch with marketing partner

Revenue growth from niche generics and first ADF product

Profitability
Base generic business profitable in 2016
R&D costs supported with ELI 200 in 2017
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News